OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NYR54

Nyrada Inc

Biotechnology & Medical ResearchVerified

Nyrada's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in the source documents. This absence of data prevents a full assessment of the company's liquidity position. The valuation snapshot does not provide additional insight into the company's financial health or market valuation. In terms of profitability and returns, Nyrada's financial data is insufficient to make a meaningful comparison with industry_config preferred metrics or cohort medians. The lack of detailed financials, including revenue, operating income, and return on invested capital, limits the ability to assess the company's performance relative to its peers. Nyrada's revenue concentration and geographic exposure are not disclosed in the available data. The company's segments and geographic breakdown are not provided, making it difficult to evaluate the diversification of its revenue streams or the risks associated with geographic concentration. The growth trajectory of Nyrada is unclear due to the absence of outlook data and revenue history. Without numeric deltas or forward-looking guidance, it is not possible to determine the company's expected growth rate or its performance in previous fiscal years. Risk factors for Nyrada include the inability to assess liquidity risk, as no balance-sheet inputs are available. The company is also at risk of dilution, although the potential is currently rated as low. No adjustments have been applied to the valuation due to the lack of data, and no specific risk factors are disclosed in the available source documents. Recent events and filings for Nyrada are not detailed in the available data. The company's 10-K Risk Factors and other disclosures are not accessible, limiting the ability to evaluate recent developments or strategic changes.

30-day price · NYR+0.06 (+11.0%)
Low$0.47High$0.67Close$0.56As of19 May, 00:00 UTC
Profile
CompanyNyrada Inc
TickerNYR.AX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Nyrada Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic tests for infectious diseases and other health conditions.

Classification. Nyrada is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Nyrada's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in the source documents. This absence of data prevents a full assessment of the company's liquidity position. The valuation snapshot does not provide additional insight into the company's financial health or market valuation. In terms of profitability and returns, Nyrada's financial data is insufficient to make a meaningful comparison with industry_config preferred metrics or cohort medians. The lack of detailed financials, including revenue, operating income, and return on invested capital, limits the ability to assess the company's performance relative to its peers. Nyrada's revenue concentration and geographic exposure are not disclosed in the available data. The company's segments and geographic breakdown are not provided, making it difficult to evaluate the diversification of its revenue streams or the risks associated with geographic concentration. The growth trajectory of Nyrada is unclear due to the absence of outlook data and revenue history. Without numeric deltas or forward-looking guidance, it is not possible to determine the company's expected growth rate or its performance in previous fiscal years. Risk factors for Nyrada include the inability to assess liquidity risk, as no balance-sheet inputs are available. The company is also at risk of dilution, although the potential is currently rated as low. No adjustments have been applied to the valuation due to the lack of data, and no specific risk factors are disclosed in the available source documents. Recent events and filings for Nyrada are not detailed in the available data. The company's 10-K Risk Factors and other disclosures are not accessible, limiting the ability to evaluate recent developments or strategic changes.
Key takeaways
  • Nyrada's liquidity position cannot be assessed due to missing balance-sheet data.
  • The company's profitability and returns are indeterminate without comparative financial metrics.
  • Revenue concentration and geographic exposure are not disclosed, limiting risk assessment.
  • Growth trajectory is unclear due to the absence of outlook data and historical revenue figures.
  • Dilution risk is low, but liquidity risk remains unassessed.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.3M-$3.5M-$3.5M-$3.5M
FY-3$1.1M-$4.0M-$4.0M-$4.0M
FY-2$1.6M-$7.8M-$7.8M-$7.8M
FY-1$3.4M-$1.4M-$1.4M-$1.4M
FY0$2.6M-$4.8M-$4.8M-$4.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$15.2M$14.5M$13.8M
FY-3$12.0M$11.5M$10.8M
FY-2$5.2M$4.3M$3.7M
FY-1$5.9M$5.1M$4.8M
FY0$5.3M$3.6M$2.9M
PeriodOCFCapExFCFSBC
FY-4-$2.8M-$5.0k-$3.5M
FY-3-$2.9M-$4.8k-$4.0M
FY-2-$7.2M$0.00-$7.8M
FY-1-$766.3k$0.00-$1.4M
FY0-$5.1M-$4.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricNYRActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 10:42 UTC#3fc2029f
Market quoteclose AUD 0.56 · shares 0.24B diluted
no public URL
2026-05-10 10:42 UTC#32e0a8b6
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 19:48 UTCJob: 5bcae325